ABL Bio (XKRX:298380) Change In Receivables : ₩475 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Change In Receivables?

ABL Bio's change in receivables for the quarter that ended in Mar. 2024 was ₩405 Mil. It means ABL Bio's Accounts Receivable declined by ₩405 Mil from Dec. 2023 to Mar. 2024 .

ABL Bio's change in receivables for the fiscal year that ended in Dec. 2023 was ₩433 Mil. It means ABL Bio's Accounts Receivable declined by ₩433 Mil from Dec. 2022 to Dec. 2023 .

ABL Bio's Accounts Receivable for the quarter that ended in Mar. 2024 was ₩0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. ABL Bio's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ABL Bio's liquidation value for the three months ended in Mar. 2024 was ₩-23,731 Mil.

ABL Bio Change In Receivables Historical Data

The historical data trend for ABL Bio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Change In Receivables Chart

ABL Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

5,190.76

-2,060.61

1,789.65

-367.01

432.60

ABL Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															363.05	-1.24	-213.74	284.53	405.40

ABL Bio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩475 Mil.

ABL Bio (XKRX:298380) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ABL Bio's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	7937.206	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, ABL Bio's accounts receivable are only considered to be worth 75% of book value:

ABL Bio's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	53218.825	-	76950.235	+	0.75 * 0	+	0.5 * 0
=	-23,731

ABL Bio Change In Receivables Related Terms

Thank you for viewing the detailed overview of ABL Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Bio (XKRX:298380) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488

Website

https://www.ablbio.com

ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio (XKRX:298380) Headlines

No Headlines